You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Azenta expects fiscal 2027 revenue of approximately $648 million to $660 million and organic growth of approximately 3% to 5%, with adjusted EBITDA margin expanding approximately 200 to 250 basis points.
Azenta reported fiscal 2026 revenue of $622 million, up 5%, but a $149 million non-cash impairment drove a ($3.50) diluted EPS loss from continuing operations. Fiscal 2027 revenue is expected to range from $648 to $660 million.
Azenta acquired SynPlexity on October 28, 2026 and entered agreements with Elegen for an exclusive five-year license, with aggregate capital deployment expected to range from approximately $32 million to approximately $71 million.
Azenta approved a restructuring plan to consolidate its North American laboratory network, reduce its workforce, close three Multiomics laboratory sites, and record approximately $11.0 million to $13.0 million in pre-tax charges, targeting approximately $11.0 million in annualized savings.
Useful current figures from the complete screener profile.
TL;DR. Azenta reported Q3 revenue of $161M (up 9% organically) and raised full-year FY26 organic revenue guidance to flat-to-up 1%, though management cautioned that Q4 organic revenue is still expected to decline low single digits due to tough comps, while adjusted EBITDA margin contracted 60 bps YoY to 11.4%.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted gross margin for Multiomics non-GAAP | 46.5% | the three months ended June 30, 2026 filing | — |
| Adjusted operating income for the SMS segment non-GAAP | $4.9M | the three months ended June 30, 2026 filing | — |
| Adjusted operating loss for the Multiomics segment non-GAAP | $0.3M | the three months ended June 30, 2026 filing | — |
| Adjusted operating margin for the Multiomics segment non-GAAP | 550 | the three months ended June 30, 2026 filing | — |
| Adjusted operating margin for the SMS segment non-GAAP | 823 | the three months ended June 30, 2026 filing | — |
| Gross margin for Multiomics | 45.6% | the three months ended June 30, 2026 filing | — |
| Gross margin for Sample Management Solutions | 44.3% | the three months ended June 30, 2026 filing | — |
| Restructuring charges | $0.5M | the three months ended June 30, 2026 filing | — |
| Adjusted earnings before interest, taxes, depreciation and amortization - Continuing operations non-GAAP | $38.91M | Nine Months Ended June 30, 2026 | — |
| Adjusted EBITDA non-GAAP | $18.5M | Third quarter fiscal 2026 | — |
| Adjusted EBITDA margin non-GAAP | 11.4% | Third quarter fiscal 2026 | — |
| Adjusted gross margin non-GAAP | 46.2% | Third quarter fiscal 2026 | — |
| Adjusted operating margin non-GAAP | 2.9% | Third quarter fiscal 2026 | — |
| Amount repurchased under the 2025 Repurchase Program | $50M | As of June 30, 2026 | — |
| Capital expenditures | $7M | Third quarter fiscal 2026 | — |
| Gross margin | 44.9% | Third quarter fiscal 2026 | — |
| Multiomics revenue | $73M | Third quarter fiscal 2026 | +10.2% |
|
|
|||
| Non-GAAP adjusted net income (loss) from continuing operations non-GAAP | $7.16M | Quarter Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net loss from continuing operations -1.53M
+2.08M Amortization of completed technology
+3.62M Amortization of other intangible assets
+272K Transformation costs
+513K Restructuring charges
+0K Impairment of goodwill and intangible assets
+2.25M Merger and acquisition costs
+0K Non-recurring other adjustments
+154K Purchase accounting adjustments
-198K Tax effect of adjustments
+0K Other adjustments
= Non-GAAP adjusted net income (loss) from continuing operations 7.16M
|
|||
| Non-GAAP adjusted net income excluding stock-based compensation - continuing operations non-GAAP | $22.43M | Nine Months Ended June 30, 2026 | — |
| Non-GAAP adjusted net income from continuing operations non-GAAP | $9.54M | Nine Months Ended June 30, 2026 | — |
| Non-GAAP adjusted operating income (loss) non-GAAP | -$1.77M | Nine Months Ended June 30, 2026 | — |
| Non-GAAP Diluted EPS non-GAAP | $0.16 | Third quarter fiscal 2026 | — |
| Operating cash flow | $1M | Third quarter fiscal 2026 | — |
| Organic revenue growth non-GAAP | 9% | Third quarter fiscal 2026 | — |
| Sample Management Solutions revenue | $88M | Third quarter fiscal 2026 | +13.4% |
|
|
|||
| Shares repurchased under the 2025 Repurchase Program | 2.3M | As of June 30, 2026 | — |
| Total cash, cash equivalents, restricted cash and marketable securities | $529M | As of June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AZTA
this stock
Azenta, Inc.
|
$2.00B | +37.3% | +3.6% | — | 12.3% |
|
ISRG
Intuitive Surgical Inc
|
$153.77B | -21.7% | +20.5% | 53.8 | 2.0% |
|
BDX
Becton Dickinson & Co
|
$59.39B | — | +8.2% | 96.5 | 3.0% |
|
MDLN
Medline Inc.
|
$51.92B | -6.0% | +11.5% | — | 2.9% |
|
ALC
Alcon Inc
|
$35.61B | -6.0% | +10.5% | — | 3.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Azenta reported fiscal 2026 revenue of $622 million, up 5%, but a $149 million non-cash impairment drove a ($3.50) diluted EPS loss from continuing operations. Fiscal 2027 revenue is expected to range from $648 to $660 million.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AZTA | +16.6% | +33.9% | +122.7% | +16.9% | +37.3% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +14.0% | +35.1% | +122.2% | +17.1% | +26.6% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
